Objective-To assess the electrophysiological and antiarrhythmic effects of pharmacological load manipulation by an angiotensin converting enzyme (ACE) inhibitor (captopril) and a direct vasodilator (hydralazine plus isosorbide mononitrate) in patients with inducible ventricular tachycardia and impaired left ventricular function.
Subjects-Eight patients with reduced left ventricular function and sustained ventricular tachycardia inducible by programmed stimulation.
Interventions-Three treatment regimens each of 48 hours duration: captopril, hydralazine plus isosorbide mononitrate, and control (no vasodilator).
Main Outcome Measures-Changes in central haemodynamics, electrophysiological parameters, and induction of ventricular tachycardia during treatment with captopril, or hydralazine combined with nitrate, compared with a control period.
Results-Both vasodilator treatments produced similar balanced reductions in peak systolic pressures and filling pressures compared with controls. Captopril had no effect on sinus cycle length, atrial refractoriness, or intraventricular conduction, but The objective of the present study was to evaluate the influence of direct vasodilators and ACE inhibitors on the arrhythmic substrate of the failing heart. Accordingly, we compared the electrophysiological effects of a hydralazine and nitrate combination and captopril, dose titrated to achieve an equivalent degree of load manipulation, in patients with left ventricular dysfunction and ventricular tachycardia induced by programmed electrical stimulation.
Patients and methods

PATIENTS
Patients with impaired left ventricular function and recurrent ventricular tachycardia referred for serial drug testing were included in the study if they fulfilled the following criteria:
(a) left ventricular ejection fraction <40%; (b) sustained (>30 s) monomorphic ventri-cular tachycardia resembling the spontaneous clinical arrhythmia induced by programmed electrical stimulation; (c) not previously established on an ACE inhibitor; (d) no amiodarone therapy within the preceding three months. They were excluded if they had had an acute myocardial infarction within the preceding two months or had clinical evidence of decompensated heart failure. Eight consecutive patients (six men, two women) with a mean (SD) age of 67 (6) years were recruited and Table 1 summarises their clinical features. All had coronary artery disease and a history of myocardial infarction with mean (SD) left ventricular ejection fraction of 24 (7)%. The study protocol was approved by the district medical ethics committee and written informed consent was obtained in all cases.
PROTOCOL
As well as routine investigations, all patients underwent left ventricular and coronary angiography and a diagnostic electrophysiological study after withdrawal of antiarrhythmic and vasoactive medication for five half lives. Left ventricular ejection fraction was estimated from the right anterior oblique view using a dedicated software package based on the Dodge formula. Patients meeting the entry criteria proceeded to a randomised open label crossover study comparing electrophysiological and haemodynamic parameters during three treatment periods, each of 48 hours duration. During two limbs of the study, subjects received active treatment with either captopril or hydralazine and isosorbide mononitrate, and during the other, control, limb they received no vasodilator. Oral antiarrhythmic drugs were withheld for the duration of the protocol. Captopril or hydralazine combined with isosorbide mononitrate were administered at eight-hourly intervals (total six doses) with blood pressure monitored every four hours by sphygmomanometry, and dose adjustment aimed at achieving a 10-20% reduction in systolic blood pressure. The starting doses were 25 mg captopril (after a test dose of 6-25 mg), and 50 mg hydralazine combined with 10 mg isosorbide mononitrate, but these were doubled if systolic pressure fell by less than 10% during the first 24 hours or halved if the fall was greater than 20%. All patients underwent combined electrophysiological and haemodynamic assessment at the end of each of the three 48 hour treatment periods. triple lumen Swan-Ganz catheter was introduced via the femoral vein to the pulmonary artery and an 18G cannula was placed in the femoral artery: these catheters were removed at the end of each study and reintroduced. After insertion of the catheters and electrodes on each occasion, patients were allowed a 15 minute rest period for stabilisation before any measurements were made. The mean and phasic arterial pressure, pulmonary artery pressure, right atrial pressure, and pulmonary capillary wedge pressure signals were recorded in held expiration with the zero reference at the mid-axillary line. Cardiac output was measured by thermodilution taking the mean of three to five consecutive measurements. The derived indices, calculated from standard equations, 8 were cardiac index, systemic vascular resistance, pulmonary vascular resistance, stroke volume index, and stroke work index. All haemodynamic measurements were duplicated after 10 minutes to ensure stability ( < 5% variation). The percentage reductions in peak systolic arterial and pulmonary artery pressures compared with the control period were used to assess changes in afterload.
Intracardiac and surface electrocardiographic signals were recorded at a paper speed of 100 mm/s with a multichannel ink jet recorder (Mingograf 7, Siemens-Elema). Pacing and extrastimuli were delivered with a 2 ms pulse width at twice diastolic threshold using a programmable stimulator (Medtronic Model 5328). In addition to sinus cycle length, QRS duration and QT interval (lead V2) were recorded during both sinus rhythm and right atrial pacing at a cycle length of 500 ms. Atrial and ventricular refractory periods were found by the extrastimulus method to the nearest 5 ms at a drive cycle length of 500 ms. After completion ofall other electrophysiological and haemodynamic measurements, programmed ventricular stimulation was performed according to a strict 12 stage protocol at the single right ventricular site: single and double extrastimuli were successively introduced during sinus rhythm and drive trains at 600, 500, and 400 ms cycle lengths (stages 1 to 8), scanning diastole with 10 ms increments; triple extrastimuli were then delivered during sinus rhythm and the same three drive cycles (stages 9 to 12). Stimulation continued until the end of stage 12 or induction of sustained monomorphic ventricular tachycardia lasting for more than 30 seconds or requiring termination before then due to haemodynamic compromise. Reproducibility was checked if the arrhythmia could be terminated by pacing, but not if a DC shock was required.
If ventricular tachycardia could be induced, conventional drug testing was performed at the end of the research study. A single intravenous dose of an appropriate antiarrhythmic agent was administered and programmed ventricular stimulation repeated. Plasma drug concentrations were then checked 48 hours later just before the next study to confirm complete removal.
STATISTICS
Continuous variables are given as mean (SD) and have been compared between the three treatment periods by multiple paired t tests, assuming the absence of any order or period effect. Values of p < 0 05 were regarded as significant. Changes in the stage at which ventricular tachycardia could be induced were assessed by the sign test.
Results
Seven patients completed all three treatment periods but one patient (No 6) was withdrawn at his own request after the captopril and control limbs. The final doses of vasodilator were captopril, 12 5 mg (n = 1), 25 mg (n = 6), 50 mg (n = 1) and hydralazine combined with isosorbide mononitrate, 50 mg and 10 mg (n = 5) and 100 mg and 20 mg (n = 2). Six patients complained of headache during hydralazine and nitrate treatment but there were no other adverse effects. Table 1 shows clinical data from the patients.
HAEMODYNAMIC CHANGES
Compared with the control period, both captopril and hydralazine combined with nitrate produced significant reductions in mean arterial and pulmonary artery pressure, with a fall in systemic vascular resistance and a rise in cardiac index (table 2). As expected, both vasodilator regimens elicited similar, balanced reductions in afterload and preload. The figure shows the mean (range) fall in peak systolic blood pressure compared with the control period. This was 15 (7-30)% with captopril and 19 (7-31)% with hydralazine and nitrate. The corresponding reductions in peak systolic pulmonary artery pressure were 26 (10-43)% for captopril and 33 (10-54)% for hydralazine and nitrate. Captopril lowered pulmonary capillary wedge pressure by 6 (1-12) mm Hg and right atrial pressure by 3 (-1 to 6) mm Hg, whereas hydralazine and nitrate reduced wedge pressure by 10 (5-18) mm Hg and right atrial pressure by 5 (1-12) mm Hg. Although the haemodynamic changes were somewhat greater with hydralazine and nitrate compared with captopril, these differences did not reach statistical significance. disappointing."' With growing awareness of the contribution of mechano-electrical and neural mechanisms to the pathogenesis of arrhythmias in the failing heart, there are theoretical grounds for expecting ACE inhibitors to exert a protective effect, but their impact on sudden death is still a matter of dispute. It has been widely reported that the beneficial effect of enalapril in the cooperative north Scandinavian enalapril survival study (CONSENSUS) was solely due to a reduction in deaths from progressive heart failure.7 This trial, however, only recruited patients with refractory end stage heart failure, among whom sudden death accounts for a relatively low proportion of total mortality (only 22% of deaths in the placebo limb of CONSENSUS), and is more likely to be mediated by a bradyarrhythmic mechanism.32 By contrast, in the captopril multicenter research group study, only one of 53 patients on active treatment died suddenly compared with eight of 52 in the placebo group.33 Fonarow et al have also reported a significantly lower sudden death rate among captopril treated patients compared with patients receiving hydralazine and nitrate in a randomised trial of 106 patients with chronic heart failure.'4 LIMITATIONS Practical considerations imposed several restrictions on the study, which should be borne in mind. We were only able to examine the shortterm electrophysiological effects of vasodilator therapy, but prolonged treatment with remodelling and reduction of venticular volumes might be required to assess the full impact of mechano-electrical feedback. Refractory periods were measured in the right ventricle, whereas the myocardial disease process and arrhythmic substrate are generally located in the left ventricle. Although similar reductions in peak systolic and filling pressures were achieved on the left and right sides of the heart, we cannot be sure that electrophysiological changes in the right ventricle accurately reflect the behaviour of diseased myocardium in the infarct border zone. Also changes in myocardial wall stress during the drive train preceding the extrastimulus may make it more difficult to assess the impact of pharmacologically induced load reduction on ventricular refractoriness. This problem could be avoided by using atrial pacing to stabilise the heart rate coupled to delivery of single ventricular extrastimuli. The use of oral rather than intravenous testing prevented us from assessing the effects of load manipulation on the endocardial monophasic action potential, a more sensitive and reliable index of ventricular repolarisation than the surface QT interval.
ELECTROPHYSIOLOGICAL CHANGES
CONCLUSIONS
We showed that load manipulation by captopril but not a hydralazine and nitrate combination prolongs ventricular refractoriness and repolarisation in patients with impaired ventricular function, possibly due to the combination of mechano-electrical feedback with inhibition ofreflex sympathetic stimulation. To answer some of the questions raised, we are conducting a further study with neurohormonal monitoring and intravenous drug administration to enable recording of changes in cardiac action potential and to avoid the confounding influence ofday to day variation in the ability to induce ventricular arrhythmias. Despite these limitations, the results of the present study support the use of ACE inhibitors rather than direct vasodilators as one component of a pharmacological strategy to prevent sudden arrhythmic deaths associated with impaired ventricular function.
